Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 67,219,936
  • Shares Outstanding, K 211,430
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.77
  • Price/Sales 5.88
  • Price/Cash Flow 13.46
  • Price/Book 5.81

Price Performance

See More
Period Period Low Period High Performance
1-Month
280.60 +13.30%
on 08/21/17
330.00 -3.66%
on 09/13/17
+36.16 (+12.83%)
since 08/18/17
3-Month
259.61 +22.46%
on 06/20/17
330.00 -3.66%
on 09/13/17
+57.39 (+22.03%)
since 06/19/17
52-Week
244.28 +30.15%
on 05/31/17
330.00 -3.66%
on 09/13/17
+38.37 (+13.73%)
since 09/19/16

Most Recent Stories

More News
Biosimilar 2017 Progress Report: Stocks in Focus

The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.

MYL : 30.98 (-1.65%)
MRK : 65.95 (-0.06%)
AGN : 215.00 (-2.95%)
NVS : 85.85 (+0.87%)
MNTA : 16.65 (-1.77%)
AMGN : 186.32 (-0.08%)
BIIB : 317.93 (-0.08%)
Alzheimer's Disease: Cannabis Formulation Shows Promise

NEW YORK, September 12, 2017 /PRNewswire/ --

ACIU : 10.92 (-2.50%)
IGC : 0.39 (+14.71%)
AVXL : 4.33 (-1.14%)
AXON : 24.27 (+6.08%)
GS : 228.91 (+0.61%)
BIIB : 317.93 (-0.08%)
Alzheimer's Disease: Cannabis Formulation Shows Promise

Known as America's most expensive disease, with an estimated cost to the U.S. economy of $236 billion in 2016, Alzheimer's disease (AD) affects more than 5.3 million Americans. Over the next 20 years,...

ACIU : 10.92 (-2.50%)
IGC : 0.39 (+14.71%)
AVXL : 4.33 (-1.14%)
AXON : 24.27 (+6.08%)
GS : 228.91 (+0.61%)
BIIB : 317.93 (-0.08%)
Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical

Biogen (NASDAQ: BIIB) announced today the appointment of Dr. Sanjay Jariwala as Senior Vice President, Worldwide Medical.

BIIB : 317.93 (-0.08%)
AbbVie Submits NDA for Endometriosis Candidate to the FDA

AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

ABBV : 86.37 (+1.23%)
RHHBY : 31.7600 (+0.59%)
BMY : 62.93 (+0.37%)
BIIB : 317.93 (-0.08%)
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley 15th Annual Global Healthcare Conference. The webcast will be live on Monday, September 11, 2017...

BIIB : 317.93 (-0.08%)
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study

Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.

NVS : 85.85 (+0.87%)
TEVA : 17.19 (+1.18%)
ADRO : 11.00 (-1.35%)
BIIB : 317.93 (-0.08%)
Watch for Biogen Inc to Potentially Pullback After Gaining 1.29% Yesterday

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $313.68 to a high of $321.73. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $316.85...

BIIB : 317.93 (-0.08%)
Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA

LONDON, UK / ACCESSWIRE / September 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) ("Ionis"), following...

IONS : 59.07 (-0.84%)
BIIB : 317.93 (-0.08%)
Biogen Alzheimer's Drug Shows Promise in Long-Term Study

Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.

JNJ : 135.22 (-0.12%)
LLY : 81.73 (-0.96%)
PFE : 35.45 (-0.28%)
BIIB : 317.93 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 320.92
1st Resistance Point 319.43
Last Price 317.93
1st Support Level 316.45
2nd Support Level 314.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.